NCT07622498 The Purpose of This Clinical Trial is to Evaluate the Accuracy of Blood Pressure Measurement of HiCardi M350 Compared to Blood Pressure Measured by Auscultatory Sphygmomanometer in Adult Volunteers (Including Those Meeting Blood Pressure Distribution Requirements) in Accordance With ISO 81060-2:2018
| NCT ID | NCT07622498 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | No Restriction on Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-06-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, single-center, single-arm pivotal clinical trial is designed to evaluate the accuracy of blood pressure measurements obtained using the HiCardi M350 patient monitor compared with measurements obtained using an auscultatory sphygmomanometer. The study will enroll adult volunteers aged 19 years or older, including participants needed to satisfy the blood pressure distribution requirements of ISO 81060-2:2018. The planned enrollment is 100 participants, considering the ISO 81060-2:2018 minimum requirement of 85 participants and an estimated dropout rate of approximately 15%. The study is also designed to obtain at least 255 valid paired blood pressure values. After written informed consent, participants will undergo screening assessments, including demographics, vital signs, medical and surgical history, prior and concomitant medications, pregnancy testing for women of childbearing potential, bilateral arm circumference measurement, eligibility assessment, and adverse event assessment. On the blood pressure test day, eligibility will be reconfirmed, an enrollment number will be assigned, HiCardi M350 calibration will be performed, and blood pressure measurements will be obtained using both HiCardi M350 and the reference auscultatory method. The primary effectiveness endpoint is the difference between systolic and diastolic blood pressure values measured by HiCardi M350 and the reference sphygmomanometer under resting conditions. Accuracy will be evaluated according to ISO 81060-2:2018 using Criteria 1 and Criteria 2. Safety will be evaluated based on adverse events, adverse device effects, serious adverse events, serious adverse device effects, unanticipated adverse device effects, and device deficiencies.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 19 years or older. 2. Individuals who visit Severance Hospital and voluntarily provide written informed consent after receiving and understanding sufficient explanation of the study. 3. Individuals with hypertension-range blood pressure may be included to meet the blood pressure distribution requirements. Participants receiving antihypertensive medication may be included only if the type and dose of medication have remained stable for at least 4 weeks before screening. Individuals with dose changes, medication additions, or medication discontinuation within 4 weeks before screening will be excluded. Exclusion Criteria: 1. Individuals in whom Korotkoff phase V cannot be clearly identified during auscultatory blood pressure measurement. 2. Individuals for whom blood pressure measurement is difficult or expected to be difficult. 3. Individuals with bilateral arm circumference greater than 42 cm. 4. Pregnant women. 5. Individuals currently participating in another clinical trial or who have participated in another clinical trial within 30 days before the screening date. 6. Individuals judged by the investigator to be inappropriate for participation in the clinical trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07622498 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying No Restriction on Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07622498 currently recruiting?
Yes, NCT07622498 is actively recruiting participants. Contact the research team at MDSUNG@yuhs.ac for enrollment information.
Where is the NCT07622498 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07622498 clinical trial?
NCT07622498 is sponsored by Yonsei University. The trial plans to enroll 100 participants.